1. Presented By:
Mr. Nitin P. Kanwale
M. Pharm. (Quality Assurance)
MVP-SAMAJ’S COLLEGE OF PHARMACY,
NASHIK02.

2. Content
 Introduction
 Synthesis of Modified protein
 Preparation of Modified Lipid Nanocarrier
 Characterisation
 Cytotoxicity Study
 Conclusion
 References

3. Introduction
 Lipoprotein Based Nanocarrier in tumor cell targeting

5. Objective of Research
 Develop the Nanocomplex that mimic the structure of
lipoprotein
 To achieve Tumour cell targeting
 To overcome shortages of lipoprotein

6. Modified protein-lipid nanocomplex
The mP-LNC was composed of a shell of selectable targeting ligand modified protein with
amphiphilic phospholipid and a core of hydrophobic lipids.

7. Synthesis and characterization of
ursodeoxycholic acid modified BSA
The carboxyl group of ursodeoxycholic acid (UA) was reactivated by EDC and
NHS and then covalently attached to the lysine residues of BSA.

8. • Degree of substitution of modified BSA • Molecular weight of modified BSA
• Surface tension measurement of modified BSA

9. Preparation of modified protein–lipid
nanocomplex (mP-LNC)
LNP was composed of PC (phosphatidylcholine), MCT (medium chain triglycerides),
octadecylamine (OL) and hydrophobic drug. nP-LNC was prepared by incubating natural BSA
with LNP. mP-LNC included uP-LNC and cP-LNC, respectively prepared by incubating UA
modified BSA (uP) and CH modified BSA (cP) with LNP.

10. Characterization of mP-LNC and LNP
 Morphology, particle size and zeta potential
 Determination of loading efficiency
Wc
WN
* 100DLE%=

11. In vitro release of coumarin-6 from nanoparticles

12. Cytotoxicity and cell uptake
test in vitro

13. Panels a–c were the fluorescence microscopy images of L02 cells after incubation with (A) LNP,
(B) c60P-LNC and (C) u60P-LNC (with 100 μg/mL of nanoparticle concentration)
at 37 °C for 2 h. Panels d–f were the fluorescence microscopy images of Bel 7402 cells after
incubation with (D) LNP, (E) c60P-LNC and (F) u60P-LNC (with 100 μg/mL of nanoparticle
concentration) at 37 °C for 2 h. Panels g–i were the fluorescence microscopy images of HepG2
cells after incubated with (G) LNP, (H) c60P-LNC and (I) u60P-LNC (with 100 μg/mL of
nanoparticle concentration) at 37 °C for 2 h.

14. Conclusion
A novel modified protein–lipid Nano complex was developed in
this study.The targeting effect of the protein–lipid Nano complex
was preliminarily proved by using coumarin-6 as fluorescence
probe in normal and cancer liver cells. It was observed that the
uptake of uP-LNC in hepatoma cells significantly increased
compared with that of cP-LNC or LNP, and was much more in
cancer cells than in normal cells. It indicated that the recognition
of UA and bile acid receptor played an important role in the
targeting delivery.
Review

15. References
 Ying Xu, Xuefeng Jin, Qineng Ping ⁎, Juan Cheng, Minjie Sun, A
novel lipoprotein-mimic nanocarrier composed of the modified
protein and lipid for tumor cell targeting delivery, Journal of
Controlled Release 146 (2010) 299–308